Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06914609 · ClinicalTrials.gov registry record · Phase 3
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
A Phase 3 study of Angelman Syndrome, sponsored by Ionis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 158
- Enrollment target
- 20
- Study locations
NCT06914609 is a Phase 3 study of Angelman Syndrome that is actively recruiting participants, run by Ionis Pharmaceuticals. The registered enrollment target is 158 participants, above the 112-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (41% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT06914609, a Phase 3 study of Angelman Syndrome, is actively recruiting participants, sponsored by Ionis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 158 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ION582
Study Locations (20)
Other
- Perth Children's Hospital - Nedlands
- Sydney Children's Hospital - Randwick
- University of Alberta Hospital - Edmonton
California
- Cedars-Sinai Medical Center - Los Angeles
- Rady Children's Hospital - San Diego
Colorado
- Colorado Children's Hospital Research Institute - Aurora
District of Columbia
- Children's National Hospital - Washington D.C.
Florida
- Nicklaus Children's Hospital - Miami
Illinois
- Rush University Medical Center - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Missouri
- Children's Mercy - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2030-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06914609
The ClinicalTrials.gov registry entry for NCT06914609 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 112-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (41% higher). The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Angelman Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06914609 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06914609 about?
NCT06914609 is a clinical study titled "REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome". The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
What is the current status of trial NCT06914609?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 158 participants. The study started on 2025-06-10. Estimated completion is 2030-04.
What conditions does trial NCT06914609 study?
This clinical trial studies the following conditions: Angelman Syndrome.
What interventions are being tested in trial NCT06914609?
The interventions under investigation include: Placebo (DRUG), ION582 (DRUG).
Who is sponsoring clinical trial NCT06914609?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06914609 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angelman Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
ACTIVE NOT RECRUITING · Phase 3
-
Angelman Syndrome Natural History Study
RECRUITING
-
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
RECRUITING · Phase 1
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
RECRUITING · Phase 2
-
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.